Trial Profile
"A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)"
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Ciclosporin
- Indications Membranous glomerulonephritis
- Focus Therapeutic Use
- Acronyms MENTOR
- 04 Jul 2019 Primary endpoint has been met. (Remission status), as per results published in the New England Journal of Medicine.
- 04 Jul 2019 Results evaluating the non inferiority of Rituximab to cyclosporine are published in the New England Journal of Medicine
- 08 Apr 2019 Status changed from active, no longer recruiting to completed.